Literature DB >> 64298

VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.

R T Eagan, D T Carr, S Frytak, J Rubin, R E Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 64298

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  10 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.

Authors:  Y Novik; L M Ryan; D G Haller; R Asbury; J P Dutcher; A Schutt
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

3.  Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group.

Authors:  F Kung; F A Hayes; J Krischer; D Mahoney; B Leventhal; G Brodeur; D H Berry; R Dubowy; S Toledano
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

Review 4.  VP16-213 (etoposide). A critical review of its activity.

Authors:  F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Epipodophyllotoxin (VP16-213) in small cell carcinoma of the Bronchus resistant to initial combination chemotherapy.

Authors:  P G Harper; M B Dally; D M Geddes; S G Spiro; J F Smyth; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 7.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.

Authors:  M E Dolan; A E Pegg; R C Moschel; B R Vishnuvajjala; K P Flora; M R Grever; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 9.  Etoposide: current status and future perspectives in the management of malignant neoplasms.

Authors:  C P Belani; L A Doyle; J Aisner
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

Authors:  H J Schmoll; N Niederle; W Achterrath
Journal:  Klin Wochenschr       Date:  1981-11-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.